| Spectrum of Activity |
- Gram-positive: Staphylococcus, Streptococcus, Corynebacterium
- Gram-negative: H. influenzae, M. catarrhalis (non-β-lactamase)
- Atypicals: Chlamydia trachomatis
- Limited: Pseudomonas, E. coli, Klebsiella
|
- Gram-positive: Staphylococcus, Streptococcus
- Gram-negative: Pseudomonas, H. influenzae, E. coli, Klebsiella
- Limited: Anaerobes, Chlamydia
|
- Gram-negative: Pseudomonas, H. influenzae, E. coli, Klebsiella, Enterobacter
- Gram-positive: Staphylococcus (including MRSA),
Mechanism of Action and Pharmacokinetics of Erythromycin Ophthalmic Ointment
Erythromycin, a macrolide antibiotic, exerts its antimicrobial effects through a well-defined biochemical pathway that distinguishes it from other antibiotic classes such as fluoroquinolones or aminoglycosides. Its pharmacokinetics, particularly in ophthalmic formulations, govern its therapeutic efficacy and safety, especially in vulnerable populations like pediatric and geriatric patients. Understanding these mechanisms and dynamics is critical for optimizing its use in ocular infections while mitigating systemic risks associated with topical administration.The macrolide class, to which erythromycin belongs, inhibits bacterial protein synthesis by binding reversibly to the 50S ribosomal subunit of susceptible microorganisms. This interaction prevents the translocation of peptidyl-tRNA from the A-site to the P-site on the ribosome, thereby halting chain elongation and leading to bacteriostatic effects. Unlike fluoroquinolones, which target DNA gyrase and topoisomerase IV to disrupt bacterial DNA replication, or aminoglycosides, which bind irreversibly to the 30S ribosomal subunit causing misreading of mRNA, erythromycin’s mechanism relies on reversible inhibition of protein synthesis. This specificity contributes to its narrower spectrum of activity, primarily effective against Gram-positive bacteria (e.g., Staphylococcus aureus, Streptococcus pneumoniae) and certain Gram-negative organisms (e.g., Haemophilus influenzae, Chlamydia trachomatis).
Biochemical Mechanism and Comparative Antimicrobial Effects
The 50S ribosomal binding site of erythromycin is located within the peptidyl transferase center, where it interferes with the formation of peptide bonds between amino acids. This inhibition is dose-dependent and reversible, allowing bacterial survival if the drug is cleared. Key distinctions from other classes include:
- Fluoroquinolones: Disrupt bacterial DNA synthesis by inhibiting topoisomerase II (DNA gyrase) and IV, leading to cell death (bactericidal). Erythromycin lacks this mechanism, restricting its use to infections where protein synthesis inhibition suffices.
- Aminoglycosides: Bind irreversibly to the 30S subunit, causing miscoding and premature termination of protein synthesis. Their bactericidal effect is concentration-dependent, unlike erythromycin’s bacteriostatic nature.
- Tetracyclines: Also inhibit protein synthesis by binding the 30S subunit but at a distinct site, leading to misreading of mRNA. Erythromycin’s 50S targeting avoids cross-resistance with tetracyclines in some bacteria.
Critical Note: Erythromycin’s bacteriostatic action makes it less effective against rapidly dividing bacteria or in immunocompromised hosts, where bactericidal agents (e.g., fluoroquinolones) may be preferred.
Pharmacokinetics of Erythromycin Ophthalmic Ointment
The pharmacokinetics of erythromycin ophthalmic ointment are influenced by ocular physiology, including tear film dynamics, corneal permeability, and systemic absorption barriers. Unlike oral erythromycin, topical administration achieves high local concentrations while minimizing systemic exposure, though absorption into the bloodstream remains a consideration.Absorption and Distribution
Erythromycin ophthalmic ointment is applied to the conjunctival sac, where it dissolves and distributes across the cornea and anterior segment of the eye. Key factors affecting its distribution include:
- Tear film turnover: Rapid blinking and tear drainage reduce corneal retention, necessitating frequent dosing (typically every 6–12 hours).
- Corneal penetration: Erythromycin’s lipophilic properties facilitate diffusion through the epithelial layer, but stromal penetration is limited due to its molecular weight (~734 Da). Intraocular levels (aqueous humor, vitreous) are generally low, restricting its use to superficial infections (e.g., blepharitis, conjunctivitis).
- Blood-ocular barriers: The blood-aqueous barrier and blood-retinal barrier limit systemic absorption, but nasolacrimal drainage allows partial absorption into the nasopharyngeal mucosa, contributing to systemic levels (~5–10% of the applied dose).
Metabolism and Elimination
Erythromycin undergoes hepatic metabolism via the cytochrome P450 3A4 (CYP3A4) enzyme, producing inactive metabolites. Elimination occurs primarily through fecal excretion (via biliary secretion) and renal clearance of metabolites. In pediatric and geriatric populations, pharmacokinetic adjustments are necessary:
- Pediatrics: Immature liver enzymes may prolong erythromycin’s half-life, increasing the risk of systemic side effects (e.g., gastrointestinal upset, ototoxicity at high doses).
- Geriatrics: Reduced hepatic blood flow and potential drug-drug interactions (e.g., with CYP3A4 substrates like warfarin or statins) necessitate cautious dosing and monitoring.
Pharmacokinetic Formula for Ocular Bioavailability:
\[ \text{Bioavailability}_{\text{ocular}} = \frac{\text{Local Concentration}_{\text{cornea}}}{\text{Applied Dose}} \times 100 \]
Topical erythromycin achieves ~1–5% systemic bioavailability, far lower than oral formulations (~30–60%), but sufficient for local infections.
Flowchart: Journey of Erythromycin Ophthalmic Ointment from Application to Systemic Effects
The following flowchart illustrates the pathway of erythromycin ophthalmic ointment from topical administration to potential systemic effects, highlighting critical barriers and dynamics:
-
Application to Conjunctival Sac
- Ointment (2–5 mg/g) is applied to the lower fornix.
- Dissolution occurs within 1–2 minutes, forming a drug reservoir.
-
Distribution in the Anterior Segment
- Corneal epithelium: Highest concentration due to lipophilicity (peak ~1–2 hours post-application).
- Tear film: Rapid dilution by lacrimal secretion (~1.5–2 µL/min), requiring frequent reapplication.
- Conjunctiva/sclera: Moderate penetration; limited to superficial layers.
-
Barriers to Posterior Segment Penetration
- Blood-aqueous barrier: Restricts aqueous humor levels to <1% of corneal levels.
- Blood-retinal barrier: Virtually no vitreous penetration; ineffective for endophthalmitis.
-
Systemic Absorption Pathways
- Nasolacrimal drainage: ~5–10% of dose absorbed via nasal mucosa, entering systemic circulation.
- First-pass metabolism: Hepatic CYP3A4 converts erythromycin to erythromycinol, reducing systemic activity.
-
Factors Influencing Local Concentration
- Tear film stability: Disruption (e.g., in dry eye syndrome) may enhance corneal retention.
- Conjunctival inflammation: Increased vascular permeability may elevate systemic levels.
- Concurrent medications: Prostaglandin analogs (e.g., latanoprost) may alter tear dynamics.
Comparison of Ocular vs. Oral Erythromycin Bioavailability
Topical erythromycin ophthalmic ointment is preferred for ocular infections due to its high local concentration-to-systemic exposure ratio, whereas oral administration achieves broader systemic distribution but lower ocular levels. The following table contrasts their pharmacokinetic profiles:
| Parameter |
Erythromycin Ophthalmic Ointment |
Oral Erythromycin |
|---|
| Peak Ocular Concentration |
10–50 µg/mL (cornea); <1 µg/mL (aqueous humor) |
Undetectable (systemic levels do not correlate with ocular penetration) |
| Systemic Bioavailability |
5–10% (via nasolacrimal absorption) |
30–60% (oral absorption, hepatic first-pass effect) |
| Half-Life |
3–5 hours (local); systemic half-life extends to 1.5–2 hours |
1
Clinical Protocols and Administration of Erythromycin Ophthalmic Ointment
Erythromycin ophthalmic ointment is administered topically to treat bacterial ocular infections, with precise dosing and application techniques critical to therapeutic efficacy and patient compliance. Proper administration ensures optimal drug distribution across the corneal and conjunctival surfaces while minimizing discomfort, particularly in vulnerable populations such as infants, the elderly, and patients with preexisting ocular conditions. This section outlines standardized protocols for administration across age groups, dosing regimens for specific indications, and specialized instructions for high-risk patients, including those with contact lenses, nasolacrimal duct obstructions, or postoperative states.
Step-by-Step Administration Techniques by Age Group
The technique for applying erythromycin ophthalmic ointment varies by age to accommodate anatomical differences and patient tolerance. Proper execution reduces trauma to delicate ocular tissues, particularly in infants, while ensuring adequate coverage in adults and the elderly. Below are standardized procedures tailored to each demographic, including dosage measurements and comfort-enhancing strategies.Infants (0–2 years)
Infants require gentle handling to prevent corneal abrasions and excessive blinking, which can displace the ointment. The recommended dosage is a 1/8-inch (0.3 cm) ribbon of ointment per eye, applied every 6–8 hours for bacterial conjunctivitis. Key steps include:
- Positioning: Lay the infant supine with the head slightly tilted back, supported by an adult’s hand or a rolled towel.
- Restraining: Use a non-dominant hand to stabilize the infant’s head while gently holding the eyelids open with the thumb and index finger of the same hand.
- Application: With the dominant hand, apply the ointment to the lower conjunctival sac (avoiding direct contact with the cornea) by gently squeezing the tube. Ensure the tip does not touch the eyelid or lashes to prevent contamination.
- Blinking Control: If the infant blinks prematurely, pause and allow relaxation before reapplying. A warm compress (sterile saline-soaked cloth) for 1–2 minutes prior to application may reduce resistance.
- Post-Administration: Massage the lacrimal sac gently for 30 seconds to facilitate distribution, especially if nasolacrimal duct obstruction is suspected.
Children (2–12 years)
Children may exhibit resistance or fear, requiring reassurance and distraction techniques. The dosage increases to a 1/4-inch (0.6 cm) ribbon per eye, administered every 6 hours for bacterial infections. Critical adjustments include:
- Explanation: Use age-appropriate language to describe the procedure as a "medicine to help the eye feel better."
- Distraction: Engage the child in conversation or a simple game (e.g., counting objects) during application to reduce anxiety.
- Application: Stand or sit facing the child, tilting their head back. Pull the lower eyelid down gently and apply the ointment to the inner corner of the eye, avoiding the cornea.
- Blinking: If resistance occurs, instruct the child to look upward while applying the ointment, then close the eyes gently for 1–2 minutes to distribute the medication.
Adults (13–64 years)
Adults typically tolerate the procedure well, but proper technique ensures even distribution. The standard dosage is a 0.5-inch (1.25 cm) ribbon per eye, applied every 6–8 hours for bacterial conjunctivitis. Key steps are:
- Hygiene: Wash hands thoroughly before and after application to prevent secondary infections.
- Positioning: Tilt the head back and pull the lower eyelid down to form a pocket. Look upward to expose the conjunctival sac.
- Application: Squeeze the tube gently to deposit the ointment along the inner lower eyelid, starting from the nasal canthus and moving outward. Avoid touching the eyelid or lashes with the tube.
- Distribution: Close the eyes gently for 1–2 minutes and instruct the patient to blink slowly to spread the ointment. A nasolacrimal occlusion (pressing the inner canthus for 30 seconds) may improve absorption in cases of epiphora.
Elderly (≥65 years)
Elderly patients may have reduced tear production, dry eyes, or cognitive impairments affecting compliance. Dosage remains 0.5-inch per eye, but frequency may be adjusted to every 8–12 hours if systemic absorption risks (e.g., hepatic impairment) are present. Special considerations include:
- Dry Eye Management: Apply artificial tears 15 minutes before erythromycin to improve ointment spread and reduce irritation.
- Assistance: If manual dexterity is limited, caregivers should administer the ointment to ensure accuracy.
- Blinking Support: Gently close the eyelids post-application and hold for 1–2 minutes to prevent ointment leakage, which can cause blurred vision.
- Monitoring: Assess for signs of corneal toxicity (e.g., photophobia, tearing) or systemic absorption (e.g., gastrointestinal upset), particularly in patients with renal or hepatic dysfunction.
Standard Dosing Regimens for Common Indications
Erythromycin ophthalmic ointment’s efficacy depends on adherence to prescribed dosing schedules, which vary by infection type, severity, and patient-specific factors. The following table summarizes evidence-based regimens for primary indications, including frequency, duration, and tapering protocols where applicable. Dosages are expressed in ribbon lengths for practical clinical use.
| Indication |
Dosage (per eye) |
Frequency |
Duration |
Tapering Schedule |
Notes |
|---|
| Bacterial Conjunctivitis (mild-moderate) |
Adults: 0.5-inch
Infants/Children: 1/8–1/4-inch |
QID (every 6 hours) |
7–10 days |
None; discontinue if symptoms resolve earlier |
Continue for 24–48 hours after symptom resolution to prevent recurrence. |
| Bacterial Conjunctivitis (severe or Chlamydia trachomatis) |
Adults: 0.5-inch
Infants: 1/8-inch |
QID–TID (every 6–8 hours) |
14 days (minimum) |
Reduce to BID for final 7 days if no signs of inflammation |
Combine with oral azithromycin (1 g single dose) for chlamydial infections. |
| Trachoma (active inflammation) |
Adults: 0.5-inch
Children: 1/4-inch |
BID–TID (every 8–12 hours) |
6 weeks (minimum) |
Transition to daily dosing for maintenance if inflammation persists |
Administer in conjunction with systemic azithromycin (20 mg/kg weekly) and face washing with clean cloths. |
| Blepharitis (marginal) |
Adults: 0.25-inch
Children: 1/8-inch |
BID–TID (before bedtime and morning) |
4–6 weeks |
Reduce to daily if symptoms improve; long-term use may be needed for chronic cases |
Combine with warm compresses and lid scrubs with baby shampoo. |
| Prevention of Neonatal Ophthalmia (prophylaxis) |
Infants: 1/8-inch in each eye |
Single dose at birth |
N/A |
N/A |
Administer within 1 hour of birth; repeat if signs of infection develop. |
Key Considerations for Dosing Adjustments
- Systemic Absorption Risk: Prolonged use (>2 weeks) or high-frequency dosing in premature infants may lead to erythromycin toxicity (e.g., pseudomembranous colitis). Monitor for diarrhea, abdominal pain, or jaundice.
- Resistance Development: Discontinuing therapy prematurely increases the risk of treatment failure
Safety Profile and Adverse Effects of Erythromycin Ophthalmic Ointment
Erythromycin ophthalmic ointment, a macrolide antibiotic, is generally well-tolerated when used for topical ocular indications. However, its safety profile must be carefully evaluated to distinguish between common transient effects and severe systemic or localized reactions. Adverse effects may arise from direct ocular irritation, allergic sensitization, or—rarely—systemic absorption, particularly in vulnerable patient populations. Understanding these risks enables clinicians to optimize therapeutic benefits while mitigating harm, especially in high-risk groups such as neonates, patients with hepatic impairment, or those with a history of macrolide allergy.The following sections categorize adverse reactions by organ system, highlight regulatory warnings, and outline monitoring protocols to ensure safe administration. Special attention is given to populations at elevated risk and alternative therapeutic strategies where applicable.
Common and Severe Adverse Reactions by System
Adverse effects of erythromycin ophthalmic ointment are predominantly localized to the eye, though systemic reactions remain a theoretical concern due to minimal absorption. The most frequently reported reactions are mild to moderate in severity, with severe systemic toxicity rare when used strictly for topical ocular purposes. Below are the categorized adverse effects, including incidence rates where documented in clinical trials or post-marketing surveillance.Ocular Adverse Effects
Erythromycin ophthalmic ointment may cause transient irritation due to its fatty base or preservatives. The most commonly reported ocular reactions include:
- Conjunctival irritation or hyperemia (incidence: ~5–10% in clinical trials), often resolving within hours to days without intervention.
- Blurred vision (incidence: ~3–5%), typically secondary to temporary corneal staining or ointment residue, resolving upon blinking or rewetting the eye.
- Chemosis (mild swelling of the conjunctiva) or itching (incidence: ~2–4%), usually self-limiting.
- Keratitis or corneal infiltrates (rare, <1%), particularly in prolonged use or concurrent trauma, potentially indicating superinfection or hypersensitivity.
Systemic Adverse Effects
Systemic absorption of erythromycin ophthalmic ointment is minimal (<1% of the dose), but rare cases of hypersensitivity or drug interactions have been documented. Reported systemic effects include:
- Allergic reactions (e.g., contact dermatitis, urticaria, or anaphylaxis; incidence: <0.1%), more likely in patients with prior macrolide exposure.
- Gastrointestinal upset (e.g., nausea, vomiting) in patients with significant systemic absorption, though this is exceedingly rare with topical ocular use.
- Hepatotoxicity (elevated liver enzymes), primarily associated with systemic erythromycin; no confirmed cases with topical ophthalmic use, but caution is advised in patients with preexisting liver disease.
Neurological and Cardiac Considerations
While systemic erythromycin is linked to QT prolongation and ventricular arrhythmias (e.g., torsades de pointes), these risks are not attributed to topical ophthalmic formulations. However, patients with underlying cardiac conditions or those receiving concurrent QT-prolonging medications (e.g., antiarrhythmics, antipsychotics) should be monitored for indirect effects, such as secondary infections requiring systemic antibiotics.
Regulatory Warnings and FDA Alerts
Erythromycin, as a macrolide antibiotic, carries black-box warnings and FDA alerts primarily related to its systemic use, which do not directly apply to topical ophthalmic formulations. However, clinicians must remain cognizant of these broader safety concerns to avoid misapplication or unnecessary systemic exposure.
FDA Black-Box Warning for Systemic Erythromycin (Relevant Context for Topical Use):
"Erythromycin has been associated with serious and potentially fatal arrhythmias, particularly when administered at high doses or in patients with underlying cardiac risk factors (e.g., congenital long QT syndrome, electrolyte imbalances). Systemic use may also cause severe hepatotoxicity, including cholestatic hepatitis and hepatic failure. Cross-sensitivity with other macrolides (e.g., azithromycin, clarithromycin) is possible."
Translation to Topical Ocular Use:
- Cardiac Risks: Topical erythromycin ophthalmic ointment does not achieve systemic concentrations sufficient to alter cardiac electrophysiology. However, if a patient requires systemic erythromycin (e.g., for concurrent infections), cumulative cardiac monitoring is warranted.
- Hepatotoxicity: No cases of liver injury have been reported with ophthalmic erythromycin alone. Patients with preexisting liver disease should still be prescribed topical erythromycin cautiously, as systemic absorption—though minimal—could theoretically exacerbate hepatic dysfunction.
- Allergic Cross-Reactivity: Patients with a history of macrolide allergy (e.g., rash, anaphylaxis to azithromycin) may experience similar reactions to topical erythromycin. Alternatives such as fluoroquinolone ophthalmic solutions (e.g., ciprofloxacin, ofloxacin) or bacitracin/polymyxin B should be considered in such cases.
Patient Populations at Higher Risk for Adverse Effects
Certain patient groups exhibit increased susceptibility to adverse reactions due to altered pharmacokinetics, immune dysregulation, or concurrent comorbidities. Below are high-risk populations, along with alternative treatments and monitoring strategies.Premature Infants and Neonates
- Risks: Premature infants have immature hepatic and renal clearance, increasing the potential for systemic absorption and toxicity. Additionally, their ocular flora is less robust, heightening the risk of superinfection or allergic sensitization.
- Monitoring: Assess for signs of systemic absorption (e.g., gastrointestinal distress, jaundice) and ocular irritation (excessive tearing, chemosis). Discontinue if signs of pseudomembranous conjunctivitis (white plaques, severe discharge) emerge.
- Alternatives: Bacitracin/polymyxin B ointment or fluoroquinolones (e.g., gatifloxacin 0.3% solution) are preferred in neonates due to lower systemic absorption and broader Gram-negative coverage.
Patients with Liver Disease
- Risks: Hepatic impairment may reduce erythromycin metabolism, though topical use minimizes systemic exposure. However, concurrent systemic macrolides could exacerbate hepatotoxicity.
- Monitoring: Evaluate liver function tests (LFTs) if systemic erythromycin is co-administered. For topical use alone, monitor for ocular irritation or delayed healing, as liver disease may impair tissue repair.
- Alternatives: Topical fluoroquinolones or sulfonamide-based ointments (e.g., sulfacetamide) are safer alternatives in patients with hepatic dysfunction.
Patients with Erythromycin Allergy
- Risks: Cross-reactivity with other macrolides (e.g., azithromycin, clarithromycin) is documented in ~10–20% of allergic patients. Topical exposure may still trigger contact dermatitis, conjunctival edema, or anaphylaxis.
- Monitoring: Observe for immediate hypersensitivity (pruritus, urticaria, angioedema) or delayed reactions (erythematous rash, eyelid swelling) within 24–72 hours of initiation. Use skin prick testing if allergy is suspected.
- Alternatives:
- First-line: Fluoroquinolone ophthalmic solutions (e.g., ciprofloxacin 0.3%).
- Second-line: Aminoglycosides (e.g., gentamicin 0.3%) or polymyxin B/trimethoprim for resistant Gram-negative infections.
Patients on QT-Prolonging Medications
- Risks: While topical erythromycin does not significantly affect QT intervals, systemic absorption in high-risk patients (e.g., those on antiarrhythmics, antipsychotics) could pose a theoretical risk.
- Monitoring: Avoid topical erythromycin in patients with baseline QT prolongation or electrolyte imbalances (hypokalemia, hypomagnesemia) unless absolutely necessary. If used, discontinue concurrent QT-prolonging drugs if possible.
- Alternatives: Topical fluoroquinolones or azithromycin ophthalmic solution (lower systemic absorption than oral erythromycin).
Monitoring for Allergic Reactions and Superinfections
Proactive monitoring is essential to distinguish between expected transient irritation and serious adverse reactions, such as allergic hypersensitivity or secondary infections. Below are diagnostic criteria and escalation protocols for common clinical scenarios.Signs of Allergic Reaction
Allergic reactions to erythromycin ophthalmic ointment may present as immediate (IgE-mediated) or delayed (cell-mediated) responses. Key indicators include:
- Immediate Reactions (within minutes to hours):
- Conjunctival hyperemia (diffuse redness beyond the treatment area).
- Periorbital edema or urticaria (suggesting systemic involvement).
- Pruritus (itching extending beyond the eyelids).
-Erythromycin ophthalmic ointment exemplifies the intersection of targeted antimicrobial therapy and ocular pharmacology, where local administration maximizes efficacy while minimizing systemic exposure. Its role in treating bacterial conjunctivitis, neonatal prophylaxis, and post-surgical infections underscores its versatility, though careful consideration of dosing, patient-specific risks, and potential interactions remains paramount. As resistance patterns evolve and alternative treatments emerge, this medication continues to serve as a reliable option—provided clinicians adhere to evidence-based protocols and vigilant monitoring. For practitioners and patients alike, its proper use ensures both therapeutic success and patient safety in managing ocular infections.
FAQ
What is erythromycin ophthalmic ointment used for in newborns?
Erythromycin ophthalmic ointment is primarily used in newborns to prevent neonatal conjunctivitis (ophthalmia neonatorum), often caused by bacterial infections like Chlamydia trachomatis or Neisseria gonorrhoeae transmitted during birth. It’s applied shortly after delivery as a routine preventive measure in many countries, though its use has declined in some places due to antibiotic resistance concerns.
What is erythromycin ophthalmic ointment used for in cats?
In cats, erythromycin ophthalmic ointment is used to treat bacterial eye infections, such as conjunctivitis or superficial keratitis (corneal ulcers). It’s also sometimes prescribed for chlamydial conjunctivitis, a common feline infectious disease, though systemic antibiotics may be needed for severe cases. Always use it as directed by a veterinarian.
What is erythromycin ophthalmic ointment used for at birth?
At birth, erythromycin ophthalmic ointment is applied to a newborn’s eyes to prevent bacterial eye infections, particularly those caused by sexually transmitted bacteria from the birth canal. This practice is part of Crede’s prophylaxis, though its effectiveness and routine use vary by region due to declining infection rates and antibiotic resistance.
What is erythromycin ophthalmic ointment used for a stye?
Erythromycin ophthalmic ointment is not typically the first-line treatment for a stye (hordeolum), which is usually caused by a bacterial infection of an oil gland near the eyelid. Warm compresses and oral antibiotics (like dicloxacillin) are more common, but erythromycin ointment may be used if the stye involves the eyelid’s outer surface or there’s concurrent eye infection.
What is erythromycin ophthalmic ointment used for in adults?
In adults, erythromycin ophthalmic ointment treats bacterial eye infections, including bacterial conjunctivitis (pink eye), blepharitis, and superficial corneal ulcers. It’s also used for chlamydial eye infections (though systemic treatment is often needed) and as a preventive measure in certain eye surgeries or injuries.
What is erythromycin ophthalmic ointment used for pink eye?
Erythromycin ophthalmic ointment is used to treat bacterial pink eye (bacterial conjunctivitis), helping reduce redness, discharge, and inflammation caused by susceptible bacteria like Staphylococcus or Streptococcus. It’s less effective for viral pink eye (most common cause) and won’t treat fungal or allergic conjunctivitis. Always confirm the cause with a healthcare provider.
|
|
Leave a Comment
Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of Voltefac.